SLC7A6 and familial pancreatic carcinoma: SLC7A6 has also been shown in murine models to regulate glutamine-dependent mTOR activation and decrease sensitivity in pancreatic cancer [33], leading to the hopes of using it as a therapeutic target for pancreatic cells.